Statin safety: an appraisal from the adverse event reporting system.

[1]  S. Wolfe.  Dangers of rosuvastatin identified before and after FDA approval , 2004, The Lancet.

[2]  P. Thompson,et al.  Statin-associated myopathy. , 2003, JAMA.

[3]  T. McGlashan,et al.  Effects of development on olanzapine-associated adverse events. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[4]  C. Black,et al.  Etiology and Frequency of Rhabdomyolysis , 2002, Pharmacotherapy.

[5]  M. Davidson.  Controversy surrounding the safety of cerivastatin , 2002, Expert opinion on drug safety.

[6]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[7]  Jennie Chang,et al.  Cerivastatin and reports of fatal rhabdomyolysis. , 2002, The New England journal of medicine.

[8]  James P. Wilson,et al.  FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis , 2002, The Annals of pharmacotherapy.

[9]  James P. Wilson,et al.  Rhabdomyolysis and HMG-CoA Reductase Inhibitors , 2001, The Annals of pharmacotherapy.

[10]  D J Graham,et al.  The role of databases in drug postmarketing surveillance , 2001, Pharmacoepidemiology and drug safety.

[11]  D. Clinch.  Ulcerogenicity of piroxicam. , 1987, British medical journal.

[12]  G. Faich,et al.  Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. , 1987, British medical journal.

[13]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[14]  S. Grundy,et al.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Stroke.

[15]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[16]  John A. Clark,et al.  Spontaneous adverse event signaling methods: classification and use with health care treatment products. , 2001, Epidemiologic reviews.

[17]  Y. Tsong,et al.  Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting. , 1995, Journal of biopharmaceutical statistics.

[18]  D. Mebs.  Side-Effects of Anti-inflammatory/Analgesic Drugs. Advances in Inflammation Research: Rainsford, K. D. and Velo, G. (Eds.) Vol. 6, 306 pp. New York: Raven Press (1984) , 1985 .